Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;11(8):e977.
doi: 10.1002/iid3.977.

Therapeutic strategies and promising vaccine for hepatitis C virus infection

Adane Adugna  1
Affiliations
Review

Therapeutic strategies and promising vaccine for hepatitis C virus infection

Adane Adugna. Immun Inflamm Dis. 2023 Aug.

Abstract

Hepatitis C virus (HCV) infection is still a significant global health problem despite therapeutic advancements. Ribavirin and interferon therapy have been the sole available treatments for HCV infection for a number of years with low efficacy. Thus, currently, a number of therapeutic strategies are being used, including nanoparticles (NPs), micro-RNAs such as small interfering RNA (siRNA), RNAi-based gene silencing and antisense oligonucleotide-based microRNA-122, microRNA-155, and short hairpin RNAs (shRNAs), and immunotherapeutic approaches such as anti-programmed cell death 1(PD-1), monoclonal antibodies (mAb or moAb), and monocyte-derived dendritic cells (Mo-DCs). Furthermore, direct-acting antivirals (DAAs) and host-targeting agents (HTA) were also the current therapeutic approaches with great efficacy. In spite of different clinical trials on HCV vaccine developments, nowadays there is no effective HCV vaccine in opposition to virus due to various challenges including genetic diversity, lack of immunocompetent small animal models, shortage of HCV vaccination testing alternatives, lack of an effective tissue culture method for replicating HCV, and inadequate knowledge regarding to immune responses against HCV infection. Nowadays, mRNA vaccine, recombinant viral vector, peptides vaccine, virus-like particles, DNA vaccine, rational designed vaccine, and recombinant polyantigenic T-cell-based vaccine are novel promising candidates for HCV vaccine based on various clinical trials. This review summarizes the different therapeutic approaches and the advancements of vaccine candidates for HCV infection.

Keywords: hepatitis C virus; promising vaccine; therapeutic strategies.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Host immunresponse induced by anti‐PD‐1 immunotherapy during chronic HCV infection. CTLA‐4, cytotoxic T lymphocyte antigen 4; HCV, hepatitis C virus; MHC, major histocompatibility complex; PD‐1/PD‐L1, programmed death‐ligand‐1; TCR, T‐cell receptor.
Figure 2
Figure 2
Induced host immunity by hepatitis C virus (HCV)‐vaccine candidates.
See this image and copyright information in PMC

References

    1. El‐Tahan RR, Ghoneim AM, Zaghloul H. 5′ UTR and NS5B‐based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt. J Adv Res. 2018;10:39‐47. - PMC - PubMed
    1. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's principles and practice of infectious diseases E‐book. Elsevier Health Sciences; 2019.
    1. Butt F, Shahid M, Hassan M, et al. A review on hepatitis C virus: role of viral and host‐cellular factors in replication and existing therapeutic strategies. Egypt Liver J. 2022;12(1):71.
    1. Heim MH. 25 years of interferon‐based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013;13(7):535‐542. - PubMed
    1. Latief U, Tung GK, Per TS, et al. Micro RNAs as emerging therapeutic targets in liver diseases. Curr Protein Pept Sci. 2022;23(6):369‐383. - PubMed